Arrowhead Pharmaceuticals Inc. (ARWR)

Arrowhead Pharmaceuticals Inc. Stock (ARWR) dropped by 26.85% from $28.98 to $21.20 in the trading on Thursday November 30, 2023. The reasons why ARWR stock down today include:

• **Net loss **: Arrowhead Pharmaceuticals, Inc. today announced its financial results for the fourth quarter and full year ended September 30, 2023. Arrowhead announced a net loss of $205.3 million for the fiscal year ended September 30, 2023, compared to a net loss of $176.1 million for the previous fiscal year.
• Missed results: Arrowhead Pharmaceuticals reported fiscal year GAAP EPS of -$1.92, missing the consensus by $0.41. Revenue of $240.73 million, slightly down from $243.2 million in the previous year. Revenue figures missed the consensus by $22.85M.
• Increase in expenses: Arrowhead Pharmaceuticals Inc's fiscal year was marked by significant investment in research and development (R&D), with expenses rising to $353.2 million from $297.3 million in the previous year. This increase reflects the company's commitment to advancing its pipeline of RNAi therapeutics.

Arrowhead Pharmaceuticals Stock (ARWR) stock decreased 3.53% to $33.32 due to some notable insider selling from the biotech’s senior leadership, namely, Tracie Oliver, ARWR’s Chief Commercial Officer.

https://seekingalpha.com/news/3986290-why-did-arrowhead-stock-dip-today